GMP – Page 20 – Pharma.Tips

Deviation history questioned during variation management – preventing PQ suspension

Managing Deviation Histories During Variation Management to Prevent PQ Suspensions In the highly regulated pharmaceutical environment, maintaining a robust deviation history is critical, particularly when navigating variation management. Organizations may…

Stability data gaps during variation management – preventing PQ suspension

Addressing Stability Data Gaps During Variation Management to Prevent PQ Suspension One common but critical issue faced by pharmaceutical manufacturers during variation management is the identification and resolution of stability…

Deviation history questioned during requalification – preventing PQ suspension

Addressing Deviation History During Requalification to Prevent PQ Suspension In the dynamic environment of pharmaceutical manufacturing, the questioning of deviation history during requalification for WHO Prequalification (PQ) can present significant…

Ineffective cleaning validation scope during multi-product campaigns – validated efficiency improvement

Enhancing Cleaning Validation for Multi-Product Campaigns: Solutions for Ineffective Scope In the pharmaceutical manufacturing landscape, ensuring compliance during multi-product campaigns can often present challenges, particularly regarding cleaning validation. Ineffective cleaning…

Manufacturing site not PQ-ready during WHO PQ assessment – CAPA expectations for PQ approval

Ensuring Your Manufacturing Site is PQ-Ready for WHO Assessments: A Comprehensive Playbook Manufacturing sites face stringent requirements during WHO Prequalification (PQ) assessments, and any deviation can lead to a determination…

PQ dossier deficiency during variation management – PQ assessment risk and mitigation

Mitigating Deficiencies in PQ Dossier During Variation Management Managing variations within the pharmaceutical manufacturing space is fraught with challenges, particularly when it comes to maintaining compliance with Prequalification (PQ) requirements…

API change not reported during requalification – documentation gaps reviewers flag

Addressing API Changes Not Reported During Requalification: A Practical Playbook In the pharmaceutical manufacturing landscape, the consequences of undocumented Active Pharmaceutical Ingredient (API) changes during requalification processes can be significant.…

Equipment downtime due to cleaning during equipment changeover – inspection-ready cleaning optimization

Optimizing Equipment Cleaning to Minimize Downtime During Changeover Downtimes during changeovers, primarily attributed to cleaning processes, are a persistent challenge in pharmaceutical manufacturing. These downtimes not only disrupt production schedules…

Tag: GMP

Deviation history questioned during variation management – preventing PQ suspension

Stability data gaps during variation management – preventing PQ suspension

Deviation history questioned during requalification – preventing PQ suspension

Ineffective cleaning validation scope during multi-product campaigns – validated efficiency improvement

Manufacturing site not PQ-ready during WHO PQ assessment – CAPA expectations for PQ approval

PQ dossier deficiency during variation management – PQ assessment risk and mitigation

API change not reported during requalification – documentation gaps reviewers flag

Equipment downtime due to cleaning during equipment changeover – inspection-ready cleaning optimization

API change not reported during dossier submission – preventing PQ suspension

Documentation not aligned to WHO during API sourcing – CAPA aligned to WHO standards

Supplier WHO GMP non-compliance during API sourcing – WHO inspector expectations explained

Inefficient CIP cycle during CPV review – validated efficiency improvement